FDA approves new treatment for advanced basal cell carcinoma (skin cancer) -7/27/15
- By Norma Cataldo
- •
- 28 Jul, 2015
- •
Odomzo is a pill taken once a day.

The U.S. Food and Drug Administration approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. Odomzo is a pill taken once a day.
It works by inhibiting a molecular pathway, called the Hedgehog pathway, which is active in basal cell cancers. By suppressing this pathway, Odomzo may stop or reduce the growth of cancerous lesions.
“Our increasing understanding of molecular pathways involved in cancer has led to approvals of many oncology drugs in difficult–to–treat diseases for which few therapeutic options previously existed,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Thanks to a better understanding of the Hedgehog pathway, the FDA has now approved two drugs for the treatment of basal cell carcinoma just in the last three years.” In 2012, Erivedge (vismodegib) was the first drug approved to treat locally advanced and metastatic basal cell carcinoma.
“Our increasing understanding of molecular pathways involved in cancer has led to approvals of many oncology drugs in difficult–to–treat diseases for which few therapeutic options previously existed,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Thanks to a better understanding of the Hedgehog pathway, the FDA has now approved two drugs for the treatment of basal cell carcinoma just in the last three years.” In 2012, Erivedge (vismodegib) was the first drug approved to treat locally advanced and metastatic basal cell carcinoma.